Inside Peptides
Search
Menu

Gastrointestinal Peptides & Gut-Brain Axis

Gastrointestinal peptide research explores regulatory hormones and mucosal cytoprotective factors that govern bowel motility, mucosal epithelial barrier integrity, visceral nociception, and fluid homeostasis. Features approved therapeutics including linaclotide and teduglutide.

Diagram of intestinal villi showing enteroendocrine L-cells, epithelial tight junctions, and enteric nervous system signaling
Enteroendocrine peptides regulate mucosal fluid secretion, nutrient absorption, and visceral pain signaling.

Field Summary & Status

Strong Evidence for Approved Drugs; Preclinical for Research Compounds
Field Maturity Clinically Validated / High
Primary Receptors Guanylate Cyclase-C (GC-C), GLP-2R, Motilin-R, SSTR2
Target Tissues Intestinal Epithelium, Enteric Nervous System, Vagal Afferents, Visceral Nociceptors
Key Approved Medicines Linaclotide (Linzess), Plecanatide (Trulance), Teduglutide (Gattex), Octreotide
Lead Investigational Classes BPC-157 (Gastric Cytoprotective), Apraglutide
Last Updated 2026-10-06

Enteroendocrine Signaling & Mucosal Homeostasis

The gastrointestinal tract is the largest endocrine organ in the human body, containing millions of specialized enteroendocrine cells scattered along the mucosal epithelium from the stomach to the rectum. These cells sample luminal contents and secrete dozens of distinct peptide hormones that coordinate digestive secretions, motor patterns, and satiety.

Pharmacological development in gastroenterology has focused on minimally absorbed, locally acting peptides. By acting exclusively on the luminal surface of enterocytes, drugs like linaclotide stimulate intestinal fluid secretion and reduce abdominal pain without systemic side effects.

Similarly, Glucagon-Like Peptide-2 (GLP-2) analogues have transformed the clinical management of short bowel syndrome by inducing mucosal crypt cell proliferation and villus growth, significantly reducing patient dependence on parenteral nutrition.

Biological Systems & Signaling Mechanisms

Luminal gastrointestinal peptides coordinate enterocyte fluid secretion, villus growth, and enteric nociception.

Detailed biological signaling pathway schematic for Gastrointestinal Peptides & Gut-Brain Axis
Integrated biological signaling pathways and physiological mechanisms in Gastrointestinal Peptides & Gut-Brain Axis.

Guanylate Cyclase-C (GC-C) / cGMP Secretion

Activation of apical GC-C elevates intracellular cGMP, opening CFTR channels to stimulate chloride and bicarbonate secretion, accelerating transit.

Evidence Domain: Epithelial Physiology

Visceral Afferent Analgesia

Extracellular cGMP transported across the basolateral enterocyte membrane inhibits submucosal pain fibers, reducing visceral hypersensitivity.

Evidence Domain: Pain Neurobiology

GLP-2R Mucosal Crypt Hyperplasia

Agonism of GLP-2 receptors on subepithelial myofibroblasts stimulates local growth factor release (IGF-1), expanding intestinal absorptive capacity.

Evidence Domain: Mucosal Biology

Peptide Classes & Molecular Targets

GI peptides divide into guanylate cyclase agonists, trophic enterokines, and somatostatin analogues.

Guanylate Cyclase-C Agonists

Target: Linaclotide (Linzess), Plecanatide
FDA-Approved for IBS-C & Chronic Idiopathic Constipation
Classification Endogenous / Synthetic
Clinical Standing FDA-Approved for IBS-C & Chronic Idiopathic Constipation
Physiological & Pharmacological Action:

Stable 14-to-16-amino-acid cyclic peptides with triple disulfide bonds that act locally in the intestinal lumen.

Key Representative Agents: Linaclotide (Linzess), Plecanatide

GLP-2 Intestinal Trophic Analogues

Target: Teduglutide (Gattex), Apraglutide
FDA-Approved for Short Bowel Syndrome
Classification Endogenous / Synthetic
Clinical Standing FDA-Approved for Short Bowel Syndrome
Physiological & Pharmacological Action:

DPP-4-resistant GLP-2 analogues that stimulate mucosal crypt cell proliferation and nutrient absorption.

Key Representative Agents: Teduglutide (Gattex), Apraglutide

Gastric Cytoprotective Fragments

Target: BPC-157
Preclinical Research; Unapproved
Classification Endogenous / Synthetic
Clinical Standing Preclinical Research; Unapproved
Physiological & Pharmacological Action:

Pentadecapeptides evaluated in preclinical animal models for gastric mucosal ulcer protection.

Key Representative Agents: BPC-157

Human Clinical Trials & Observational Data

Large multicenter Phase 3 trials demonstrate bowel transit acceleration and mucosal regeneration.

Trial / Study Identifier / Compound Phase & Cohort Status / Duration Primary Findings
Trial of Linaclotide in Patients With IBS-C (26-week Phase 3)
Trial of Linaclotide in Patients With IBS-C (26-week Phase 3)
NCT00938717 		Phase 3 Double-Blind RCT
804 IBS-C patients over 26 weeks
 Completed 33.7% of linaclotide-treated patients met the FDA composite responder end point vs 13.9% with placebo (P < 0.0001); abdominal pain and complete spontaneous bowel movement end points also improved.
Published 2012
STEPS Phase 3 Teduglutide in Short Bowel Syndrome
STEPS Phase 3 Teduglutide in Short Bowel Syndrome
NCT00798967 		Phase 3 Double-Blind RCT
86 short bowel syndrome patients dependent on PN
 Completed 63% of teduglutide patients (27/43) vs 30% with placebo (13/43) achieved a >20% reduction in parenteral support volume at weeks 20 and 24.
Published 2012

Approved Medicines vs. Investigational Compounds

Clear distinction between regulatory-approved prescription medicines and experimental candidates undergoing laboratory or early clinical testing.

Compound Target / Mechanism Regulatory Status Indications / Focus Sponsor / Developer
Linaclotide (Linzess) Approved Biological Target FDA/EMA Approved (2012) IBS-C & Chronic Idiopathic Constipation Ironwood / AbbVie
Teduglutide (Gattex) Approved Biological Target FDA/EMA Approved (2012) Short Bowel Syndrome Dependent on Parenteral Nutrition Takeda
Apraglutide Long-acting synthetic GLP-2 analogue Phase 3 Development Preclinical / Investigational VectivBio / Ironwood
BPC-157 Gastric mucosal cytoprotection Preclinical / Unapproved Preclinical / Investigational Academic Research

Safety Realities & Clinical Tolerability

Locally acting GI peptides minimize systemic toxicity but can induce dose-dependent fluid alterations.

Dose-Dependent Diarrhea

Mild to Moderate

Severe diarrhea is the primary adverse reaction for GC-C agonists, resulting from excessive luminal chloride secretion.

Colorectal Polyp Growth with GLP-2

Moderate / Surveillance Mandated

Because GLP-2 stimulates mucosal cell proliferation, patients require surveillance colonoscopy to monitor for pre-existing polyps.

Unresolved Scientific Questions

Key mechanistic and translational questions currently under active scientific investigation.

Can orally administered cytoprotective peptides heal inflammatory bowel disease?

While preclinical BPC-157 shows anti-inflammatory effects in murine DSS colitis, controlled human Phase 2 trials in Crohn's or ulcerative colitis have never been completed.

Does the gut-brain axis mediate central mood changes through GI peptide signaling?

Evaluating whether reducing peripheral gut nociception directly alters central anxiety and depressive symptoms.

Evolution of Research & Milestones

Historical scientific breakthroughs, isolation events, structural discoveries, and regulatory milestones.

1996

GLP-2 Trophic Action Discovered

Drucker and colleagues discover that GLP-2 specifically induces intestinal crypt cell growth.

2012

Linaclotide & Teduglutide Approvals

FDA approves both Linzess and Gattex in landmark year for GI peptide therapeutics.

2026

Next-Gen Enterokines

Once-weekly GLP-2 analogues (apraglutide) enter registrational review.

Scientific References

Primary scientific publications, randomized controlled trials, and clinical consensus papers referenced in this field overview.

  1. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety Chey WD et al. Am J Gastroenterol 2012. Am J Gastroenterol · 2012
    Source
  2. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure Jeppesen PB et al. Gastroenterology 2012. Gastroenterology · 2012
    Source
  3. Induction of intestinal epithelial proliferation by glucagon-like peptide 2 Drucker DJ et al. Proc Natl Acad Sci USA 1996. Proc Natl Acad Sci U S A · 1996
    Source

Scientific & Educational Disclaimer

InsidePeptides.org provides scientific and educational analysis of peer-reviewed research for informational purposes only. This overview does not constitute medical advice, diagnosis, treatment, prescription, or clinical guidance. Incretin and metabolic peptide medicines require physician oversight, prescription authorization, and regular clinical monitoring. Never adjust, initiate, or discontinue prescribed treatments without direct consultation with a qualified medical specialist.